alcian-blue and Abnormalities--Drug-Induced

alcian-blue has been researched along with Abnormalities--Drug-Induced* in 2 studies

Other Studies

2 other study(ies) available for alcian-blue and Abnormalities--Drug-Induced

ArticleYear
Repairability of skeletal alterations induced by sodium valproate in rats.
    Congenital anomalies, 2018, Volume: 58, Issue:3

    The present study aimed at examining postnatal repairability of sodium valproate-induced skeletal alterations in rats. Sodium valproate (400 mg/kg) or the vehicle (distilled water) was orally administrated to pregnant Sprague-Dawley rats from gestation days 9 to 11. Fetuses and pups were obtained on gestation day 21 and postnatal day 11, respectively, and their skeletons were stained with Alizarin red S and Alcian blue and examined. Sodium valproate-induced costal and vertebral alterations in the fetuses included discontinued rib cartilage, fused rib, full or short supernumerary rib, bipart ossification of thoracic centrum, supernumerary lumbar vertebrae, and lumbarization. In pups, however, discontinued rib cartilage was not observed, and the incidence of a short supernumerary rib was significantly lower than that in the fetuses, suggesting that these alterations are postnatally repairable.

    Topics: Abnormalities, Drug-Induced; Administration, Oral; Alcian Blue; Animals; Animals, Newborn; Anthraquinones; Anticonvulsants; Bone Regeneration; Cartilage; Female; Fetus; Gestational Age; Lumbar Vertebrae; Maternal Exposure; Musculoskeletal Abnormalities; Pregnancy; Rats; Rats, Sprague-Dawley; Ribs; Thoracic Vertebrae; Valproic Acid

2018
Murine teratology of fluconazole: evaluation of developmental phase specificity and dose dependence.
    Pediatric research, 2005, Volume: 58, Issue:1

    The potential of in utero exposure to fluconazole to initiate teratogenesis was analyzed in ICR (CD-1) mice. Developmental phase specificity was determined by treating mice with single oral doses of 700 mg/kg on gestational day 8, 9, 10, 11, or 12. Control animals received vehicle on gestational days 8-12. Gestational day 10 was identified as the phase of maximal sensitivity for induction of cleft palate, the predominant teratogenic effect induced by fluconazole, with 50% of fetuses exposed on this developmental phase being affected. After treatments on gestational day 8, 9, 11, or 12, cleft palate occurred with lower frequencies: 12, 21, 28.7, and 2.7%, respectively. Examination of skeletal morphology revealed anomalies of the middle ear apparatus in 15% of the fetuses that were exposed on gestational day 8. Dysmorphic tympanic ring and absence of the incus were the more common ear anomalies recorded. Reduced humeral length was noted in 22% of fetuses that were exposed on gestational day 10. Dose-response relationship was investigated by treating animals with 0 (vehicle), 87.5, 175, or 350 mg/kg on gestational day 10, coincident with the phase of peak teratogenic sensitivity. Besides showing that fluconazole operates under a strict dose-response mechanism, the study identified 175 mg/kg as the lowest observed adverse effect level for cleft palate induction, with 7.6% of the exposed fetuses being affected.

    Topics: Abnormalities, Drug-Induced; Alcian Blue; Animals; Anthraquinones; Antifungal Agents; Body Weight; Cartilage; Cleft Palate; Dose-Response Relationship, Drug; Ear, Middle; Female; Fluconazole; Forelimb; Mice; Mice, Inbred ICR; Pregnancy; Pregnancy, Animal; Teratogens; Teratology; Time Factors

2005